OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.
Vol. 26/No. 6
The EBMT have developed a machine learning model designed to identify and stratify transplant risk for patients with myelofibrosis.
Liquid biopsy approaches aid in precision therapy selection for patients with breast cancer in a noninvasive manner.
A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.
Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target
Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.
In an OncLive Peer Exchange, expert investigators convened to discuss the treatment landscape of early-stage NSCLC from a multidisciplinary perspective.
Maurie Markman, MD, explores the key role of clinical judgment in treatment decision-making and its impact on patient outcomes in cancer research.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5